Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

BackgroundEffective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.MethodsWe bring pioneering contribu...

Full description

Bibliographic Details
Main Authors: Rafaella F. Q. Grenfell, Nathalie B. F. Almeida, Priscilla S. Filgueiras, Camila A. Corsini, Sarah V. C. Gomes, Daniel A. P. de Miranda, Adelina J. Lourenço, Olindo A. Martins-Filho, Jaquelline G. de Oliveira, Andrea Teixeira-Carvalho, Guilherme R. F. Campos, Mauricio L. Nogueira, Pedro Augusto Alves, Gabriel R. Fernandes, Leda R. Castilho, Tulio M. Lima, Daniel P. B. de Abreu, Renata G. F. Alvim, Thaís Bárbara de S. Silva, Wander de J. Jeremias, Dayane A. Otta, Ana Carolina Campi-Azevedo, Immunita-001 Team, Priscila Fernanda S Martins, Maria Luysa C Pedrosa, Jessica V de Assis, Viviane CF dos Santos, Eduardo R de Oliveira, Raphael A Silva, Maria Izabella VARC Medeiros, Rafaela OV Coelho, Cecilia MF Bicalho, Raquel VR Vilela
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
vaccine
immune response
coronavac
BNT162b2
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.918896/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.918896/full

Similar Items